SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4069)6/7/2001 9:51:13 PM
From: IRWIN JAMES FRANKEL  Respond to of 52153
 
A PDLI question:

Will the Mab's made with the older PDLI methods, after some time, face an immune response and become ineffective?

ij



To: Biomaven who wrote (4069)6/8/2001 3:59:04 AM
From: nigel bates  Respond to of 52153
 
<<MEDX and ABGX>>

CAT, of course, are cheaper still, though legal uncertainties probably contribute to that. Might be well worth a look when they sort out a Nazdaq listing.

nig



To: Biomaven who wrote (4069)6/8/2001 11:07:36 AM
From: Michael Young  Read Replies (1) | Respond to of 52153
 
Looks like KOSP upgraded by Cowen today. I have not seen any details.

MIKE


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News